Conference
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients with Eosinophilic Granulomatosis with Polyangiitis
Abstract
OBJECTIVE: The Phase 3 MANDARA study demonstrated non-inferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab-treated patients achieved complete withdrawal of oral glucocorticoids (OGCs). These post-hoc analyses further elucidate the efficacy of benralizumab and mepolizumab in facilitating reductions in OGCs.
METHODS: Adults with EGPA requiring …
Authors
Nair PK; Hellmich B; Bourdin A; Jayne DRW; Roufosse F; Khalidi N; Sjö LB; Fan Y; McCrae C; Necander S
Publisher
Wiley
Publication Date
September 22, 2025
DOI
10.1002/art.43398
Conference proceedings
Arthritis & Rheumatology
ISSN
2326-5191